J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 2310KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 102(6): 473-476, 2001

Feature topic

LYMPH NODE DISSECTION IN LUNG CANCER

1) Department of Chest Surgery, Tokyo Medical University, Kasumigaura Hospital, Ibaraki, Japan
2) Department of Surgery, Tokyo Medical University, Tokyo, Japan

Makoto Saito1), Toyoaki Miura1), Kinya Furukawal1), Harubumi Kato2)

The standard surgical treatment for stage I, II, and IIIa non-small cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection. In our series of 214 patients with N2 disease the 5-year survival rate was 23%. Systematic mediastinal lymph node dissection provides further prognostic information on the N factor. Among NSCLC patients with a pathological diagnosis of N2, there are significant differences in the 5-year survival rate based the 3 factors of clinical N factor, N1 station metastasis, and N2 station metastasis.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.